- For US Healthcare Professionals Only
- Important Safety
Information - Indication
- Prescribing
Information - Patient
Website
FINANCIAL
ASSISTANCE
The cost for ORGOVYX may differ based on your patients' insurance coverage. How much patients pay depends on their coverage. We can help you find out what your patients' costs may be. Call 1-833-ORGOVYX (1-833-674-6899) to request an insurance benefit review.
MEDICARE
75%of patients pay $100 or
less per month for ORGOVYX1*
MEDICAID
>80%of patients pay
$0 a month1*
COMMERCIAL
>80%of patients pay as
little as $10 per month1*
*Statistics represented as average costs paid per month, as of January 15, 2024. Symphony Claims Data, December 2022-November 2023. Calculated based on 30-day supply, excluding reversed, rejected, and null value claims. Data may not represent claims not captured in the Symphony dataset.
For Medicare Part D
PATIENTS
Important changes to Medicare Part D costs could impact your patients.
Use this resource to find out more.
For eligible commercially insured patients
Pay as little as $10
per month
As a part of the ORGOVYX Copay Assistance Program, eligible, commercially insured patients may pay as little as $10 per prescription, with a maximum savings per calendar year of $10,000. See program terms and conditions below.†
The ORGOVYX Support Program may be able to help those patients who are not eligible for an ORGOVYX
Savings Card or need additional assistance. Call the ORGOVYX Support Program at 1-833-ORGOVYX (1-833-674-6899).
ORGOVYX Copay Assistance Program Terms, Conditions, and Eligibility Criteria
†Eligibility required. Commercially insured patients only. This copay program is subject to a calendar year maximum savings of $10,000. After the calendar year maximum savings is reached, patient will be responsible for the remaining out-of-pocket costs for ORGOVYX. The Copay Program is not valid for patients participating in Medicare, Medicaid, or other government healthcare programs. No membership fees. This offer is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for ORGOVYX. Terms and conditions apply. For full program terms, conditions, and eligibility criteria please visit www.orgovyx.com/terms-and-conditions.
ORGOVYX NATIONAL COVERAGE
99% of Medicare patients are covered for ORGOVYX1‡
93% of commercial patients are covered for ORGOVYX1‡
SEE FORMULARY COVERAGE
IN YOUR AREA
IN YOUR AREA
‡This coverage information is provided for informational purposes only; individual plans vary, and this may not include all plans. Sumitomo Pharma America and Pfizer make no representation or guarantee concerning coverage or reimbursement for ORGOVYX; please check with individual payers for plan-specific coverage and reimbursement information and requirements. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced. This information is subject to change without notice. Data on file. Formulary data are provided by MMIT, LLC, as of December 2024. Transaction data are provided by SHS database as of December 2024.1
Back to Top 
IMPORTANT SAFETY INFORMATION & INDICATION
Contraindication
ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.
Warnings and Precautions
QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported in post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated.
Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.
Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.
Adverse Reactions
Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.
Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).
Drug Interactions
Co-administration of ORGOVYX with a P-gp inhibitor increases the area under the curve (AUC) and maximum concentration (Cmax) of ORGOVYX, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks for a short course of treatment with certain P-gp inhibitors. If treatment with ORGOVYX is interrupted for more than 7 days, resume administration of ORGOVYX with a 360 mg loading dose on the first day, followed by 120 mg once daily.
Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases the AUC and Cmax of ORGOVYX, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.
INDICATION
ORGOVYX® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Please see full Prescribing Information for ORGOVYX.
Reference:
- Data on file. Sumitomo Pharma America, Inc.